In conclusion, our study demonstrated that BAG2 serves as an oncogene that promotes and exacerbates the mutant p53 aggregates by recruiting HSP90, and consequently contributes to chemoresistance in breast cancer. Here, BAG2 is linked to breast carcinoma.